Toggle Main Menu Toggle Search

Open Access padlockePrints

Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene

Lookup NU author(s): Professor Alan Calvert, Dr Martin Highley, Professor John LunecORCiD, Professor Alan Boddy


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


In this pharmacokinetic and dose-escalation study of the carboplatin/paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combination, patients were randomly assigned to receive paclitaxel either as a 1-hour or a 3-hour infusion. The 1-hour infusion was feasible, with maximum tolerated doses similar to those previously reported for a 3-hour infusion. Using patients' age, height, plasma creatinine, and plasma creatine kinase provided an improved estimate of the glomerular filtration rate compared with the more traditional creatinine-based formulas according to population analysis of data derived from glomerular filtration rate estimates performed by an isotope method. Studies of the p53 gene sequence of ovarian tumors at diagnosis suggest that p53 mutations are a potent predictor of response to subsequent treatment with carboplatin.

Publication metadata

Author(s): Calvert, A. H., Ghokul, S., Al-Azraqi, A., Wright, J., Lind, M., Bailey, N., Highley, M., Siddiqui, N., Lunec, J., Sinha, D., Boddy, A. V., Roberts, F., Fenwick, J.

Publication type: Article

Publication status: Published

Journal: Seminars in Oncology

Year: 1999

Volume: 26

Issue: 1 supplement 2

Pages: 90-94

Print publication date: 01/02/1999

ISSN (print): 0093-7754

ISSN (electronic): 1532-8708


PubMed id: 10190788